+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

mRNA Platform Market by mRNA Type, mRNA Molecule, Application, Indication, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5460245
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The mRNA Platform Market grew from USD 13.52 billion in 2023 to USD 16.33 billion in 2024. It is expected to continue growing at a CAGR of 21.44%, reaching USD 52.71 billion by 2030.

The mRNA platform is a transformative biotechnology landscape that primarily entails using messenger RNA (mRNA) for therapeutic and vaccine development. The need for mRNA technology is driven by its ability to instruct cells to produce proteins that can prevent or treat diseases, offering rapid development cycles, flexible manufacturing, and potent efficacy. The critical applications include vaccines, notably for infectious diseases like COVID-19, and therapeutics for cancer, rare genetic disorders, and possibly chronic diseases. The end-use scope of mRNA spans pharmaceutical and biotech companies, research institutions, and healthcare providers, eager for novel treatment modalities. Market growth is propelled by increased R&D investments, advances in delivery technologies, and growing acceptance of genetic medicines. Opportunities abound in areas like personalized cancer immunotherapy, development of non-viral delivery systems, and potential expansion into diverse therapeutic areas. These can be seized by leveraging collaborative efforts across biotech firms and research institutions, focusing on the unmet needs of diseases lacking effective treatment. However, this market faces challenges, including high production costs, storage, and distribution issues, particularly the need for ultra-cold chain logistics for vaccines. Regulatory hurdles and public acceptance are additional barriers that could impede progress. Yet, innovation opportunities lie in improving delivery mechanisms, enhancing mRNA stability and storage conditions, and expanding the platform’s efficacy and safety profile. There’s room to innovate in creating mRNA vaccines for diseases that mutate quickly or have no vaccines, like HIV. The market is highly dynamic, characterized by rapid technological advancements and competitive dynamics among key players seeking to differentiate through cutting-edge solutions. To thrive, stakeholders must remain agile, prioritize strategic partnerships, and invest in expanding the portfolio of mRNA-based applications, enhancing market penetration and addressing unmet healthcare needs.

Understanding Market Dynamics in the mRNA Platform Market

The mRNA Platform Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing development of vaccines to meet the rising need for global health preparedness
    • Rising availability of mRNA treatments and vaccines with increasing advancements in the biomedical field
      Biotech Breakthroughs Propel mRNA Treatments and Vaccines to New Heights in Speed and Scalability
    • Increased funding to fuel breakthroughs in mRNA therapeutics and healthcare advancements
    • Growing need for mRNA therapy with the rising prevalence of chronic diseases
  • Market Restraints
    • High production costs limiting the widespread adoption and scalability of mRNA-based medical treatments
    • Regulatory hurdles and lengthy approval processes slowing down mRNA platform development and market entry
  • Market Opportunities
    • Integration of mRNA platforms to transform personalized medicine with precision therapies
    • Growing potential of mRNA technology in non-vaccine therapeutic areas
    • Rapid acceleration for the development and commercialization of mRNA-based therapies through robust collaborations with pharmaceutical companies
  • Market Challenges
    • Limited cold chain infrastructure for storing and distributing mRNA-based treatments
    • Potential safety and immunogenicity concerns for acceptance and widespread use of mRNA therapies

Exploring Porter’s Five Forces for the mRNA Platform Market

Porter’s Five Forces framework further strengthens the insights of the mRNA Platform Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the mRNA Platform Market

External macro-environmental factors deeply influence the performance of the mRNA Platform Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the mRNA Platform Market

The mRNA Platform Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the mRNA Platform Market

The mRNA Platform Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the mRNA Platform Market

The mRNA Platform Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the mRNA Platform Market, highlighting leading vendors and their innovative profiles. These include Acuitas Therapeutics Inc., Arcturus Therapeutics Holdings, Inc., Beam Therapeutics Inc., BioNTech SE, Catalent, Inc., CureVac N.V., Daiichi Sankyo Company, Limited, Danaher Corporation, eTheRNA Immunotherapies NV, Ethris GmbH, FUJIFILM Holdings Corporation, Gritstone bio, Inc., In-Cell-Art, Merck KGaA, Moderna Inc., Novo Nordisk A/S, Pfizer Inc., Precision BioSciences, Inc., Regulus Therapeutics Inc., Sangamo Therapeutics, Inc., Sanofi SA, Takara Bio Inc., Telesis Bio Inc., Thermo Fisher Scientific Inc., Tiba Biotech LLC, TriLink BioTechnologies by Maravai LifeSciences, and Verve Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the mRNA Platform Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • mRNA Type
    • Nucleoside-Modified mRNA
    • Unmodified mRNA
  • mRNA Molecule
    • Monocistronic mRNA
    • Polycistronic mRNA
  • Application
    • Drugs
    • Vaccines
  • Indication
    • Autoimmune Diseases
    • Cancer
    • Infectious Diseases
    • Respiratory Diseases
  • End-User
    • Hospitals & Clinics
    • Pharmaceutical Companies
    • Research & Academic Institutiions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing development of vaccines to meet the rising need for global health preparedness
5.1.1.2. Rising availability of mRNA treatments and vaccines with increasing advancements in the biomedical field
Biotech Breakthroughs Propel mRNA Treatments and Vaccines to New Heights in Speed and Scalability
5.1.1.3. Increased funding to fuel breakthroughs in mRNA therapeutics and healthcare advancements
5.1.1.4. Growing need for mRNA therapy with the rising prevalence of chronic diseases
5.1.2. Restraints
5.1.2.1. High production costs limiting the widespread adoption and scalability of mRNA-based medical treatments
5.1.2.2. Regulatory hurdles and lengthy approval processes slowing down mRNA platform development and market entry
5.1.3. Opportunities
5.1.3.1. Integration of mRNA platforms to transform personalized medicine with precision therapies
5.1.3.2. Growing potential of mRNA technology in non-vaccine therapeutic areas
5.1.3.3. Rapid acceleration for the development and commercialization of mRNA-based therapies through robust collaborations with pharmaceutical companies
5.1.4. Challenges
5.1.4.1. Limited cold chain infrastructure for storing and distributing mRNA-based treatments
5.1.4.2. Potential safety and immunogenicity concerns for acceptance and widespread use of mRNA therapies
5.2. Market Segmentation Analysis
5.2.1. mRNA Type: Ability of nucleoside-modified mRNA to balance immune response efficacy with reduced side effects and offer enhanced stability
5.2.2. mRNA Molecule: Requirement of monocistronic mRNA for the development of precise, targeted therapies
5.2.3. Application: Expanding need for quick and effective production of vaccines through novel mRNA platforms
5.2.4. Indication: Increasing prevalence of cancer cases worldwide
5.2.5. End-User: Extensive involvement of pharmaceutical companies in the marketing and authorization of mRNA platforms
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. mRNA Platform Market, by mRNA Type
6.1. Introduction
6.2. Nucleoside-Modified mRNA
6.3. Unmodified mRNA
7. mRNA Platform Market, by mRNA Molecule
7.1. Introduction
7.2. Monocistronic mRNA
7.3. Polycistronic mRNA
8. mRNA Platform Market, by Application
8.1. Introduction
8.2. Drugs
8.3. Vaccines
9. mRNA Platform Market, by Indication
9.1. Introduction
9.2. Autoimmune Diseases
9.3. Cancer
9.4. Infectious Diseases
9.5. Respiratory Diseases
10. mRNA Platform Market, by End-User
10.1. Introduction
10.2. Hospitals & Clinics
10.3. Pharmaceutical Companies
10.4. Research & Academic Institutiions
11. Americas mRNA Platform Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific mRNA Platform Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa mRNA Platform Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Cipla Boosts Investment in Ethris to Accelerate mRNA-Based Respiratory Therapies for Emerging Markets
14.3.2. Arcturus Therapeutics to Present Promising Early Data on Inhaled mRNA Treatment for Cystic Fibrosis at European Conference
14.3.3. Merck Invests Over Euro 300 Million in New Research Center Focused on mRNA and Antibody Development
14.3.4. CureVac and MD Anderson Collaborate on mRNA-Based Cancer Vaccines for Unmet Medical Needs
14.3.5. VBI Vaccines Inc.'s Advancement in mRNA Vaccine Technology with Government of Canada Support
14.3.6. Blackstone Commits USD 750 Million to Support Moderna's Influenza Vaccine Development and Commercialization
14.3.7. Novo Holdings Acquires Catalent for USD 16.5 Billion, Plans Strategic Site Sales to Novo Nordisk
14.3.8. TriLink BioTechnologies and FUJIFILM Toyama Chemical Forge Partnership to Enhance mRNA Drug Development and Manufacturing Efficiency
14.3.9. Ethris Launches First Human Trial of Innovative Inhaled RNA Therapy for Virus-Induced Asthma
14.3.10. Moderna Inc. Advances mRNA Research with New Australian Incubator Network and Vaccine Manufacturing Facility
14.3.11. Bill & Melinda Gates Foundation Invests USD 40 Million in Affordable mRNA Vaccine Manufacturing for Low-Income Nations"
14.3.12. Merck and Moderna Launch Global Phase 3 Trial for Advanced Melanoma Therapy
14.3.13. Applied DNA Sciences Enhances mRNA Manufacturing with Spindle Biotech Acquisition, Aims to Improve Yields and Reduce Costs
14.3.14. Sensible Biotechnologies and Ginkgo Bioworks Forge Strategic Alliance for Revolutionizing mRNA Production
14.4. Strategy Analysis & Recommendation
14.4.1. Pfizer Inc.
14.4.2. Moderna, Inc.
14.4.3. Sanofi SA
14.4.4. Ethris GmbH
List of Figures
FIGURE 1. MRNA PLATFORM MARKET RESEARCH PROCESS
FIGURE 2. MRNA PLATFORM MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. MRNA PLATFORM MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. MRNA PLATFORM MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. MRNA PLATFORM MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. MRNA PLATFORM MARKET DYNAMICS
TABLE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY NUCLEOSIDE-MODIFIED MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY UNMODIFIED MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY MONOCISTRONIC MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY POLYCISTRONIC MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MRNA PLATFORM MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MRNA PLATFORM MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MRNA PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MRNA PLATFORM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. CANADA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 42. CANADA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 43. CANADA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. CANADA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 45. CANADA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. MEXICO MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 47. MEXICO MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 48. MEXICO MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. MEXICO MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 50. MEXICO MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. CHINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 69. CHINA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 70. CHINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. CHINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. CHINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. INDIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 74. INDIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 75. INDIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. INDIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. INDIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. JAPAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 84. JAPAN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 85. JAPAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. JAPAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. JAPAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. THAILAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 114. THAILAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 115. THAILAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. THAILAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. THAILAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 129. DENMARK MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 130. DENMARK MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 131. DENMARK MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. DENMARK MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. DENMARK MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. EGYPT MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 135. EGYPT MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 136. EGYPT MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. EGYPT MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. EGYPT MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. FINLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 140. FINLAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 141. FINLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. FINLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. FINLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. FRANCE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 145. FRANCE MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 146. FRANCE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. FRANCE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. GERMANY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 150. GERMANY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 151. GERMANY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. GERMANY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 153. GERMANY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. ITALY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 160. ITALY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 161. ITALY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. ITALY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. ITALY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. NORWAY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 175. NORWAY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 176. NORWAY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. NORWAY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. NORWAY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. POLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 180. POLAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 181. POLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. POLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. POLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. QATAR MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 185. QATAR MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 186. QATAR MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. QATAR MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. SPAIN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 205. SPAIN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 206. SPAIN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. SPAIN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 208. SPAIN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. TURKEY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 220. TURKEY MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 221. TURKEY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. TURKEY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 223. TURKEY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY MRNA MOLECULE, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. MRNA PLATFORM MARKET SHARE, BY KEY PLAYER, 2023
TABLE 235. MRNA PLATFORM MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the mRNA Platform Market, which are profiled in this report, include:
  • Acuitas Therapeutics Inc.
  • Arcturus Therapeutics Holdings, Inc.
  • Beam Therapeutics Inc.
  • BioNTech SE
  • Catalent, Inc.
  • CureVac N.V.
  • Daiichi Sankyo Company, Limited
  • Danaher Corporation
  • eTheRNA Immunotherapies NV
  • Ethris GmbH
  • FUJIFILM Holdings Corporation
  • Gritstone bio, Inc.
  • In-Cell-Art
  • Merck KGaA
  • Moderna Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Precision BioSciences, Inc.
  • Regulus Therapeutics Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Takara Bio Inc.
  • Telesis Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Tiba Biotech LLC
  • TriLink BioTechnologies by Maravai LifeSciences
  • Verve Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information